Mannkind (MNKD) Stock Analysis: AI Score & Alternative Data
MNKD alt-data: revenue climbing, job postings lagging
Is Mannkind a buy right now? The alternative data says hold. This MNKD stock analysis is built on the 25+ alternative data signals AltIndex tracks on Mannkind every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 51/100: a Hold. The stock trades at $4.06 with a $1B market cap.
The bullish side of the 90-day ledger: revenue up 37.5% YoY to $110M, and 74% of employees are positive on the business outlook. The drag: job postings down 27.0% to 27 open roles, web traffic down 25.0% to 16K monthly visits, and sentiment down 8.6% to 64/100. That tension is what keeps the score mid-range.
MNKD’s broader alt-data profile also covers headcount (867 employees, according to LinkedIn), and X followers (3K). Every signal links to its own page with full history, the MNKD technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on MNKD is just below.
Mannkind AI Stock Analysis
Mannkind is a biopharmaceutical company primarily focused on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's flagship product, Afrezza, is an inhalable insulin that offers an alternative to injectable insulin.
Analysis generated September 4, 2026.
Recent Mannkind Stock Alerts
|
Mannkind | August 19 Price is up by 6.3% in the last 24h. |
|
Mannkind | August 7 Price is up by 6% in the last 24h. |
|
Mannkind | August 6 Price is down by -7.1% in the last 24h. |
|
Mannkind | July 30 Price is up by 6.2% in the last 24h. |
Mannkind Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 16K | 25.0% | |
| Job Posts | 27 | 27.0% | |
| LinkedIn Employees | 867 | 3.8% | |
| Employee Recommend | 80 | 0% | |
| Business Outlook | 74 | 0% | |
| Sentiment | 64 | 8.6% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 98.3% | |
| Stocktwits Mentions | 318 | 57.5% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 42K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 3K | 0% | |
| Instagram Followers | 1K | 3.9% | |
| Youtube Subscribers | 280 | 1.4% | |
| Facebook Followers | 2K | 1.1% | |
| Facebook Engagement | 0 | 100.0% |
About Mannkind (MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
| Price | $4.06 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $1B |
| Year Range | $2 – $6 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Mannkind News
View more → |
How Investors May Respond To MannKind (MNKD) Winning FDA Approval For At‑Home Furoscix AutoinjectorJuly 25 - Biztoc.com |
 |
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney DiseaseJuly 24 - Biztoc.com |
MannKind Corporation (MNKD) Up 20% Since Afrezza FDA ApprovalJuly 9 - Yahoo Entertainment |
|
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”June 13 - Yahoo Entertainment |
|
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2MMay 17 - Yahoo Entertainment |
|
See Mannkind’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for MNKD, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEMannkind Earnings & Financial Performance
View all earnings →Mannkind Insider Trading Activity
View all →| Binder Steven B. filed to sell 785,867 shares at $0.0. Aug 7 '26 |
| Binder Steven B. filed to sell 824,918 shares at $0.0. Jul 17 '26 |
| Thomson David filed to sell 797,554 shares at $0.0. Jul 17 '26 |
| Thomson David filed to sell 826,299 shares at $0.0. May 12 '26 |
| Binder Steven B. filed to sell 808,008 shares at $0.0. May 12 '26 |
Mannkind Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Mannkind
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Vor BiopharmaVOR |
$25.05 3.3% | $1B | 43 |
 |
MoonLake ImmunotherapeuticsMLTX |
$15.01 1.2% | $1B | 46 |
 |
Alpha Tau MedicalDRTS |
$15.03 2.8% | $1B | 41 |
 |
Odyssey TherapeuticsODTX |
$28.76 8.9% | $1B | 46 |
 |
MeiraGTx HldgsMGTX |
$13.89 0.6% | $1B | 52 |
Explore Mannkind Data
Frequently Asked Questions: Mannkind (MNKD)
Mannkind has an AltIndex AI Score of 51/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
51/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Mannkind (MNKD) stock is $4.06 with a market cap of $1B.
As of today, Mannkind’s PE (Price to Earnings) ratio is —.
View the latest Mannkind insider transactions to see recent buying and selling activity by company executives and directors.
Check the Mannkind congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The MNKD stock price chart above shows Mannkind’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Mannkind technical analysis for RSI, moving averages, and more.
See the stocks similar to Mannkind section on this page for companies in the same industry ranked by market cap and AI Score.
